Telix Pharmaceuticals Limited (TLX) Stock Overview
Explore Telix Pharmaceuticals Limited’s financial performance, market position, analyst ratings, and future outlook.
Telix Pharmaceuticals Limited (TLX)
Key Financials
Key Financials
Market Cap
4B
P/E Ratio
-526.41
EPS (TTM)
$-0.02
ROE
-0.02%
TLX Stock Analysis & Investment Overview (NASDAQ)
Our AI-powered analysis of Telix Pharmaceuticals Limited (NASDAQ: TLX) gives investors deep insight into how the stock performs on the NASDAQ exchange, its growth potential, and its market positioning. With a Meyka AI Score of C+, Telix Pharmaceuticals Limited's NASDAQ-listed shares demonstrate moderate investment characteristics based on our machine learning models.
The current technical analysis of TLX on the NASDAQ shows an RSI of 61.50, suggesting the stock is in a a neutral condition. Our forecasting models predict a 12-month price target of $4.82 for the NASDAQ listing.
Key metrics behind Telix Pharmaceuticals Limited's NASDAQ-traded stock include a P/E ratio of -526.41 and a market capitalization of 4B. Combined with our AI analysis, these give both institutional and retail investors a clear view of TLX on the NASDAQ.